Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
被引:0
|
作者:
Horesh, Adi
论文数: 0引用数: 0
h-index: 0
机构:
Hebrew Univ Jerusalem, Fac Med, Jerusalem, IsraelHebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Horesh, Adi
[1
]
Pollack, Rena
论文数: 0引用数: 0
h-index: 0
机构:
Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, IsraelHebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Pollack, Rena
[1
,2
]
Nechushtan, Hovav
论文数: 0引用数: 0
h-index: 0
机构:
Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, IsraelHebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Nechushtan, Hovav
[1
,3
]
Dresner-Pollak, Rivka
论文数: 0引用数: 0
h-index: 0
机构:
Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, IsraelHebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Dresner-Pollak, Rivka
[1
,2
]
Neuman, Tzahi
论文数: 0引用数: 0
h-index: 0
机构:
Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, IsraelHebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
Neuman, Tzahi
[1
,4
]
机构:
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel
[4] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Wang, Yuanyuan
Gu, Tingxuan
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Gu, Tingxuan
Tian, Xueli
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Tian, Xueli
Li, Wenwen
论文数: 0引用数: 0
h-index: 0
机构:
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Li, Wenwen
Zhao, Ran
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Zhao, Ran
Yang, Wenqian
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Yang, Wenqian
Gao, Quanli
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Affiliated Canc Hosp, Dept Immunol, Zhengzhou, Peoples R China
Henan Canc Hosp, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Gao, Quanli
Li, Tiepeng
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Affiliated Canc Hosp, Dept Immunol, Zhengzhou, Peoples R China
Henan Canc Hosp, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Li, Tiepeng
论文数: 引用数:
h-index:
机构:
Shim, Jung-Hyun
Zhang, Chengjuan
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Affiliated Canc Hosp, Dept Pathol, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Zhang, Chengjuan
Liu, Kangdong
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R ChinaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
Liu, Kangdong
Lee, Mee-Hyun
论文数: 0引用数: 0
h-index: 0
机构:
Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China
China US Henan Hormel Canc Inst, Zhengzhou, Peoples R China
DongShin Univ, Coll Korean Med, Naju, South KoreaZhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China